| Primary |
| Product Used For Unknown Indication |
30.6% |
| Benign Prostatic Hyperplasia |
22.9% |
| Depression |
6.3% |
| Hypertension |
4.9% |
| Prostatic Disorder |
4.9% |
| Urinary Retention |
4.2% |
| Bladder Obstruction |
3.5% |
| Cardiovascular Disorder |
2.8% |
| Dysuria |
2.8% |
| Hypertonic Bladder |
2.1% |
| Prostate Cancer |
2.1% |
| Urinary Tract Disorder |
2.1% |
| Blood Cholesterol |
1.4% |
| Diabetes Mellitus |
1.4% |
| Drug Use For Unknown Indication |
1.4% |
| Glucose Tolerance Impaired |
1.4% |
| Nocturia |
1.4% |
| Postoperative Hernia |
1.4% |
| Prostatomegaly |
1.4% |
| Residual Urine |
1.4% |
|
| Syncope |
12.8% |
| Product Substitution Issue |
8.5% |
| Transient Ischaemic Attack |
8.5% |
| Alcohol Interaction |
4.3% |
| Death |
4.3% |
| Delirium |
4.3% |
| Drug Interaction |
4.3% |
| Eyelid Ptosis |
4.3% |
| Feeling Abnormal |
4.3% |
| Interstitial Lung Disease |
4.3% |
| Intervertebral Disc Protrusion |
4.3% |
| Miosis |
4.3% |
| Nausea |
4.3% |
| Nephritis |
4.3% |
| Presyncope |
4.3% |
| Renal Failure Acute |
4.3% |
| Residual Urine |
4.3% |
| Sensation Of Pressure |
4.3% |
| Tachycardia |
4.3% |
| Abdominal Distension |
2.1% |
|
| Secondary |
| Benign Prostatic Hyperplasia |
20.0% |
| Product Used For Unknown Indication |
18.8% |
| Drug Use For Unknown Indication |
12.7% |
| Hypertension |
10.8% |
| Hypercholesterolaemia |
3.5% |
| Diabetes Mellitus |
3.1% |
| Bladder Disorder |
2.7% |
| Hypertonic Bladder |
2.7% |
| Postoperative Hernia |
2.7% |
| Prostatomegaly |
2.7% |
| Asthma |
2.3% |
| Depression |
2.3% |
| Nocturia |
2.3% |
| Prostatic Disorder |
2.3% |
| Dysuria |
1.9% |
| Prostatic Adenoma |
1.9% |
| Pyrexia |
1.9% |
| Renal Cell Carcinoma |
1.9% |
| Urinary Tract Disorder |
1.9% |
| Anxiety |
1.5% |
|
| Syncope |
11.8% |
| Hyperthyroidism |
5.9% |
| Myalgia |
5.9% |
| Orthostatic Hypotension |
5.9% |
| Presyncope |
5.9% |
| Renal Failure Acute |
5.9% |
| Sexual Dysfunction |
5.9% |
| Testicular Pain |
5.9% |
| Blood Sodium Decreased |
3.9% |
| Cardiac Failure |
3.9% |
| Completed Suicide |
3.9% |
| Dizziness |
3.9% |
| Drug Ineffective |
3.9% |
| Drug Interaction |
3.9% |
| Dyspnoea |
3.9% |
| Dysuria |
3.9% |
| Gastritis |
3.9% |
| Pulmonary Fibrosis |
3.9% |
| Rheumatoid Arthritis |
3.9% |
| Sinusitis |
3.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.0% |
| Drug Use For Unknown Indication |
11.9% |
| Hypertension |
11.8% |
| Benign Prostatic Hyperplasia |
9.1% |
| Type 2 Diabetes Mellitus |
4.0% |
| Diabetes Mellitus |
3.8% |
| Prostate Cancer |
3.4% |
| Pain |
3.4% |
| Prophylaxis |
3.2% |
| Atrial Fibrillation |
2.5% |
| Hiv Infection |
2.3% |
| Constipation |
2.2% |
| Smoking Cessation Therapy |
2.2% |
| Prostate Cancer Stage Iv |
2.1% |
| Hypercholesterolaemia |
1.8% |
| Depression |
1.8% |
| Gastrooesophageal Reflux Disease |
1.8% |
| Rheumatoid Arthritis |
1.7% |
| Premedication |
1.6% |
| Multiple Myeloma |
1.5% |
|
| Drug Ineffective |
8.0% |
| Renal Failure Acute |
7.7% |
| Weight Increased |
6.6% |
| Nausea |
6.3% |
| Rhabdomyolysis |
6.1% |
| Vomiting |
6.1% |
| Death |
5.5% |
| Weight Decreased |
5.2% |
| Anaemia |
4.7% |
| Pyrexia |
4.7% |
| Urinary Retention |
4.7% |
| Drug Interaction |
4.4% |
| Pneumonia |
4.4% |
| Interstitial Lung Disease |
4.1% |
| Thrombocytopenia |
4.1% |
| Haematuria |
3.6% |
| Rash |
3.6% |
| White Blood Cell Count Increased |
3.6% |
| Muscular Weakness |
3.3% |
| Respiratory Failure |
3.3% |
|
| Interacting |
| Hypertension |
16.2% |
| Benign Prostatic Hyperplasia |
8.1% |
| Type 2 Diabetes Mellitus |
8.1% |
| Back Disorder |
5.4% |
| Back Pain |
5.4% |
| Bladder Obstruction |
5.4% |
| Blood Pressure High |
5.4% |
| Depression |
5.4% |
| Fibromyalgia |
5.4% |
| Irritable Bowel Syndrome |
5.4% |
| Vitamin D Deficiency |
5.4% |
| Acid Reflux (Esophageal) |
2.7% |
| Allergy |
2.7% |
| Atrial Fibrillation |
2.7% |
| Atrial Flutter |
2.7% |
| Blood Cholesterol Abnormal |
2.7% |
| Blood Cholesterol Increased |
2.7% |
| Cardiovascular Event Prophylaxis |
2.7% |
| Drug Use For Unknown Indication |
2.7% |
| Erectile Dysfunction |
2.7% |
|
| Drug Interaction |
50.0% |
| Myocardial Infarction |
12.5% |
| Syncope |
12.5% |
| Trismus |
12.5% |
| Ventricular Extrasystoles |
12.5% |
|
